Anika Therapeutics reported $-3285000 in Pre-Tax Profit for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Pre Tax Profit Change
Abbott ABT:US $ 2973M 926M
Agenus AGEN:US $ -50.6M 17M
Agios Pharmaceuticals AGIO:US $ -91.81M 2.97M
Anika Therapeutics ANIK:US $ -3.28M 0.42M
Arrowhead Research ARWR:US $ -72.05M 116.41M
Chemocentryx CCXI:US $ -38.61M 1.92M
Clovis Oncology CLVS:US $ -60.29M 2.06M
Enanta Pharmaceuticals ENTA:US $ -33.59M 3.44M
Halozyme Therapeutics HALO:US $ 81.63M 20.43M
Heron Therapeutics HRTX:US $ -63.89M 9.24M
Immunogen IMGN:US $ -62.02M 37.88M
Insmed INSM:US $ -95144000 908K
Intrexon XON:US $ -19.31M 5.71M
Karyopharm Therapeutics KPTI:US $ -48941000 7.67M
Ligand Pharmaceuticals LGND:US $ 12.57M 26.39M
Macrogenics MGNX:US $ -66.44M 8.42M
Peregrine Pharmaceuticals PPHM:US $ 0.59M 1.66M
Rigel Pharmaceuticals RIGL:US $ -13.49M 13.95M
Sangamo Biosciences SGMO:US $ -43.09M 0.83M
Sanofi SAN:FP € 2660M 305M
Veracyte VCYT:US $ -9.65M 4.82M
Xencor XNCR:US $ -33.98M 57.57M